Open access
Aug 2026
P256 - ECE_2728 - Impact of setmelanotide on metabolic index scores in Phase 3 trial participants with acquired hypothalamic obesity
The findings highlight the broad metabolic benefits and strong clinically meaningful efficacy of setmelanotide in this population, supporting its potential as a therapeutic option for patients with aHO and suggest reductions in visceral fat burden, hepatic steatosis, and overall cardiometabolic risk.
H. V. van Santen, S. Phillips, J. Hamilton et al.
· European Journal of Endocrin... · 0 citations